Evolving Landscapes in Multiple Myeloma

This article summarizes 2 analyses from the phase 3 GMMG-HD7 trial presented at ASH 2024, as well as the FDA’s Oncologic Drugs Advisory Committee support for the use of minimal residual disease as an accelerated approval endpoint in multiple myeloma clinical trials.

In this article, the results from 2 studies of Isa-KRd in newly diagnosed multiple myeloma (NDMM) are summarized, with the GMMG-CONCEPT trial focusing on high-risk NDMM and the IFM 2020-02 MIDAS study focusing on transplant-eligible NDMM.

This article summarizes a post-hoc analysis of data from the MASTER study and the GRIFFIN study of patients with newly diagnosed multiple myeloma with high-risk cytogenetic abnormalities.

This article summarizes results from an ad hoc survey conducted to evaluate nurses’ experiences with subcutaneous isatuximab administration via an on-body delivery system.

Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma.

This article summarizes results of the phase 3 IMROZ study, including the frailty subgroup analysis.

Results of the BENEFIT study provide evidence that a weekly bortezomib regimen in isatuximab plus bortezomib, lenalidomide, and dexamethasone can be an effective and feasible option for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

The results of CEPHEUS support the use of daratumumab-based quadruplet therapy for transplant-ineligible or -deferred newly diagnosed multiple myeloma (NDMM).